The Latest On Transapical: Edwards Talks Up Sapien CAP Data
This article was originally published in The Gray Sheet
Executive Summary
The non-randomized continued access program, which enrolled 822 transapical patients beyond the original randomized enrollment of 104 transapical patients, tells an improving story for transapical delivery for Sapien.
You may also be interested in...
Edwards Reveals Sapien Launch Plans For Transapical Delivery Method
Edwards estimates that the approximately 20%-30% of patients who would otherwise qualify but can’t receive a Sapien valve because their femoral artery is too small would likely make good candidates for the transapical, through the ribcage, route.
Market & Industry Briefs
Brief summaries of recent medtech market and industry developments. This month we cover news from the TAVI space, ConforMIS’ customized knee implants, and Siemens’ recent companion diagnostic dealmaking.
Transcatheter Valve Coverage Proposal Reflects Stricter Medicare Environment
CMS’ proposed national coverage determination comes only three months after the approval and launch of Edwards Lifesciences’ Sapien, the first transcatheter aortic valve in the U.S. It restricts coverage to FDA-approved indications and includes a coverage-with-evidence-development provision.